The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

These data support a paradigm shift in the treatment of locally advanced rectal cancer.

Treatment for community-acquired pneumococcal disease is dependent on patient-specific factors, whereas prevention with vaccinations is dependent on age and comorbidities.

In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.

Nivolumab plus ipilimumab combination improved overall survival, with 21% of individuals with metastatic non–small cell lung cancer treated with the combination and 2 cycles of chemotherapy alive compared to 16% with chemotherapy alone.

Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.

It’s imperative to redefine the future of pharmacy to help ensure a robust pipeline of future pharmacists and create a culture that helps ensure pharmacists live their purpose and passion.

Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.

Current standard of care gives 2 poor options to patients, neither of which cure grade 2 gliomas.

Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.

Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.

Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.

Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.

Biliary tract cancers have become the model for precision oncology because of its complex molecular landscape.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Identifying alterations in tumor genes has enabled medical oncologists to guide patients towards more specific therapies.

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

Findings presented at the American Society of Clinical Oncology (ASCO) 2023 meeting show the long-term efficacy and safety profile of larotrectinib (Vitrakvi; Bayer) in solid tumors with NTRK gene fusion.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.